 Home > Medical News > Latest Medical News > Has invested 350 million yuan in Hengrui's topical JAK1 inhibitor phase II clinical success

Has invested 350 million yuan in Hengrui's topical JAK1 inhibitor phase II clinical success

 Last Update: 2021-10-21
 Source: Internet
 Author: User

Tags

ulcerative colitis diarrhea

aleve anti inflammatory

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 11, Hengrui Medicine announced that the double-blind, excipient-controlled, phase II/III phase II/III seamless adaptive design clinical study RSJ10431 (MARBLE23) of SHR0302 alkali ointment for the treatment of atopic dermatitis developed by its subsidiary Ruishi Biotechnology Among them, the 0.

The results of the study showed that patients who received topical 0.

From: Corporate Announcement

This is the first domestically-made innovative drug of JAK1 inhibitor for external use that has entered clinical trials in China

The RSJ10431 study that reached the end point was led by Professor Xu Jinhua from Huashan Hospital of Fudan University as the main investigator.

Ruishi Biology will communicate with the drug supervision department regarding the above-mentioned research results and follow-up clinical development plans, and initiate SHR0302 base ointment for the phase III clinical treatment of mild to moderate atopic dermatitis as soon as possible

Atopic dermatitis is a chronic inflammatory skin disease with complex lesions and diverse clinical manifestations and symptoms.

SHR0302 alkali ointment is a topical, highly selective JAK1 inhibitor, which can exert anti-inflammatory and immune-suppressing biological effects by inhibiting JAK1 signal transduction

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.